Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Jiang, Yunyun ^a   Subbiah, Vivek ^a   Janku, Filip ^a   Ludwig, Joseph A ^a   Naing, Aung ^a   Benjamin, Robert S ^a   Brown, Robert E ^b   Anderson, Pete ^a,c   Kurzrock, Razelle ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Levine Children's Hospital   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CHILD; DESMOPLASTIC SMALL ROUND CELL TUMOR; EWING SARCOMA; GENETICS; HUMAN; MIDDLE AGED; MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; DESMOPLASTIC SMALL ROUND CELL TUMOR; GRB10 ADAPTOR PROTEIN; HUMANS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; YOUNG ADULT;

EID: 84905915756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093676     Document Type: Article

References (39)

1. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, et al. (2009) Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 10: 126-140.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
3. Sawyer JR, Tryka AF, Lewis JM (1992) A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am J Surg Pathol 16: 411-416.
4. Gerald WL, Rosai J, Ladanyi M (1995) Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci U S A 92: 1028-1032.
5. Ladanyi M, Gerald WL (1996) Specificity of the EWS/WT1 gene fusion for desmoplastic small round cell tumour. J Pathol 180: 462.
6. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, et al. (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694-701. (Pubitemid 36237038)
7. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, et al. (2004) Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22: 2873-2876. (Pubitemid 41079906)
8. Naing A, Kurzrock R (2010) Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer 9: E1-4.
9. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, et al. (2011) Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17: 6052-6060.
10. Naing A, Lorusso P, Fu S, Hong DS, Anderson P, et al. (2012) Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. Clin Cancer Res.
11. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, et al. (2011) Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One 6: e18424.
12. Subbiah V, Kurzrock R (2012) Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med 13: 405-415.
13. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, et al. (2010) A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465.
14. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, et al. (2011) R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 6: e26060.
15. Philippe-Chomette P, Kabbara N, Andre N, Pierron G, Coulomb A, et al. (2012) Desmoplastic small round cell tumors with EWS-WT1 fusion transcript in children and young adults. Pediatr Blood Cancer 58: 891-897.
16. Hayes-Jordan A, Anderson PM (2011) The diagnosis and management of desmoplastic small round cell tumor: a review. Curr Opin Oncol 23: 385-389.
17. Quaglia MP, Brennan MF (2000) The clinical approach to desmoplastic small round cell tumor. Surg Oncol 9: 77-81.
18. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
19. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
20. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, et al. (2012) Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18: 748-757.
21. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, et al. (2013) Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget 4: 884-889.
22. Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, et al. (2013) Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One 8: e68985.
23. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332: 1317-1322.
24. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332: 1322-1326.
25. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, et al. (2009) The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 106: 9435-9440.
26. Lai R, Navid F, Rodriguez-Galindo C, Liu T, Fuller CE, et al. (2006) STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol 208: 624-632.
27. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
28. Vilar E, Tabernero J (2012) Cancer: Pinprick diagnostics. Nature 486: 482-483.
29. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
30. Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, et al. (2010) Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66: 605-609.
31. Zhang W, Zong CS, Hermanto U, Lopez-Bergami P, Ronai Z, et al. (2006) RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage- independent growth. Mol Cell Biol 26: 413-424. (Pubitemid 43089756)
32. Ma PC, Kijima T,Maulik G, Fox EA, Sattler M, et al. (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281. (Pubitemid 37255174)
33. To CT, Tsao MS (1998) The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep 5: 1013-1024. (Pubitemid 28372555)
34. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, et al. (2007) c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13: 2246-2253. (Pubitemid 46649894)
35. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, et al. (2009) Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15: 5714-5723.
36. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, et al. (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744-1748. (Pubitemid 350274378)
37. Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254.
38. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. (Pubitemid 37328931)
39. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573. (Pubitemid 40799249)